# Contact RxPT141: The PT-141 Editorial Desk

> Contact RxPT141 — the editorial desk behind this PT-141 (bremelanotide) research digest. For corrections and source questions only; no medical or dosing advice.

Corrections, source questions, and citation pointers — the editorial channel, not a clinical one.

## What to write in about

RxPT141 is an editorial digest, so this channel is for editorial matters: corrections to a summary, questions about which source backs a particular claim, broken citation links, or suggestions for published studies we should add. If you spot a figure that does not match its cited source, tell us — getting the record right is the entire point of the site.

## What we cannot help with

We cannot answer medical or personal-dosing questions, and we do not provide consultations, prescriptions, or product sourcing. Questions about whether PT-141 is right for any individual, what dose to use, or where to obtain it belong with a licensed clinician, not with an editorial desk. We also cannot verify the contents of any "research chemical" material — unregulated PT-141 has no oversight of identity, purity, or concentration, and we report that rather than advise on it.

## Reaching us

Use the form below for corrections and source questions. Include the page, the bracketed citation number, and what you believe is off, and we will check it against the original source. We read every message about the accuracy of the record; we do not respond to dosing, sales, or sourcing requests because this site neither dispenses nor sells anything.

---

A blue-phosphor terminal reading of the PT-141 (bremelanotide) record — the one approved use logged first, the label dose and trial figures read back verbatim, the off-label and research-chemical lines flagged amber, and the unverified field reports fenced off as such; no clinic behind the prompt and nothing here dosed, sourced, prescribed, or sold.